The FDA granted Krystal Biotech orphan status for its treatment of Alpha-1 antitrypsin deficiency.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech announces sale of PRV for $100M
- Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
- Krystal Biotech price target raised to $153 from $148 at Chardan
- Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
- Krystal Biotech reports Q2 EPS ($1.25), consensus (74c)